Nabanita Nawar, a Bangladeshi researcher and entrepreneur residing in Canada, has been featured on Forbes’ “30 Under 30 Local Toronto.”
This is the first-ever such list by Forbes, and Nabanita stands as the sole Bangladeshi representative.
Forbes on Wednesday revealed the names and achievements of the 30 accomplished individuals based in Toronto, Canada.
Who is Nabanita Nawar?
Dr Nabanita Nawar is the CEO and Co-Founder of HDAX Therapeutics. She has a PhD in medicinal chemistry, and BSc in biological chemistry from the University of Toronto.
Nawar has over eight years of experience in drug discovery, leadership, governance, and science policy.
Her capabilities earned her the “2022 Rising Star” distinction from the Ontario Institute for Cancer Research (OICR).
She also received the “Canadian Silver Medal” from the Chemical Institute of Canada.
Forbes’ website mentions that HDAX Therapeutics is developing the first-ever therapy for peripheral neuropathy (PN). It affects over 30 million people worldwide.
PN patients suffer from nerve damage that causes sensation loss, immobility and even paralysis. At present, there is no existing treatment capable of slowing, or reversing the progression of this disease.
However, HDAX is on the path to potentially administer doses to patients as early as 2025.
Nawar, and her partner, Pimyupa Manaswiyoungkul, filed multiple patents and partnered with top cancer research clinics worldwide.
Based in Toronto, the company emerged from five years of academic research conducted at the University of Toronto. The company has successfully raised over $800,000 in funding.
